Gilead continues M&A surge with $3.1B deal for ADC specialist Tubulis
BioPharma Dive
Gilead s third acquisition since late February hands it a technology designed to make antibody-drug conjugates less toxic and multiple prospects already in clinical testing.
Gilead outlays $5bn to acquire ADC specialist Tubulis
Pharmaceutical Technology
Sixteen months after partnering with Tubulis, Gilead has decided to acquire the biotech and its portfolio of ADCs.
Gilead Swallows Another Partner, Paying up to $5B for ADC Specialist Tubulis
BioSpace
The acquisition of Tubulis GmbH–Gilead Sciences’ latest of the year after buying Arcells and Ouro Medicines–brings into the fold a novel ovarian cancer candidate that has demonstrated promising mid-st
219: An Interview With Dr. Natalie Truba on the Psychological Aspects of Gene Therapy
Rare Disease Audio
Larry Luxner, senior correspondent for Rare Disease Advisor, interviews pediatric psychologist Natalie Truba, PhD, on the psychological aspects of gene therapy in neuromuscular disease.
Gilead strikes again, penning $5bn deal to buy Tubulis
Pharmaphorum
Gilead has signed its third acquisition deal since the start of the year, agreeing to buy ADC specialist Tubulis for $3.15bn upfront.
AbbVie Puts Humira on TrumpRx at Steep Discount as Tariff Threat Solidifies
BioSpace
Humira will be available on TrumpRx at an 86% discount, according to media reports, as part of AbbVie’s deal with the White House to avoid tariffs.
Kennedy changes vaccine panel charter after legal setback
Pharmaphorum
A change to the ACIP charter has raised concerns of even greater political influence over the vaccine panel by HHS Secretary Kennedy.
Amgen reports positive phase 3 results for subcutaneous TEPEZZA in thyroid eye disease
PharmaTimes
Subcutaneous delivery shows IVlevel efficacy in moderate to severe TED
FDA Seeks Expanded Authority To Regulate Postapproval Manufacturing Changes
BioSpace
Aiming to protect patients, the FDA sent lawmakers a wish list of legislative proposals intended to clarify and expand its oversight of updates to approved drug production processes.
CatalYm begins phase 2b trial of visugromab in second-line liver cancer treatment
PharmaTimes
Study expands development of the antibody into hepatocellular carcinoma
In the face of tariffs, FDA-approved drug manufacturing deals are shifting to Europe
Pharmaceutical Technology
In 2025, biopharma companies increasingly invested in Europe-based contract manufacturing for FDA-approved drugs compared to US-based providers.
Sanofi Bispecific Scores in Asthma, Rhinosinusitis, but Eczema Bet Doesn’t Pay Off
BioSpace
Sanofi has faced questions about the potential of lunsekimig in eczema, with executives calling the clinical trial a “measured risk.”
Sanofi immune drug hopeful posts mixed results in mid-stage tests
BioPharma Dive
Lunsekimig, a bispecific drug aimed at two popular targets, succeeded in studies in asthma and nasal polyps but missed its mark in an eczema trial.
AI giant Anthropic buys Coefficient Bio for $400m
Pharmaphorum
Anthropic has continued its push into the healthcare sector by acquiring New York start-up Coefficient Bio.
Amgen Seeks ‘Return to Growth’ for Tepezza as More Convenient Formulation Aces Phase 3
BioSpace
Sales of Amgen’s thyroid eye disease drug Tepezza have slowed, dipping 1% to $457 million in the fourth quarter of 2025.
Amgen scores with new thyroid eye disease formulation
Pharmaphorum
Can Amgen’s subcutaneous version of Tepezza inject renewed growth into the thyroid eye disease blockbuster?
FDA floats new clinical trial reforms; Takeda punts Denali brain drug
BioPharma Dive
In its budget request, the agency proposed a way to speed up early drug testing and help smaller biotech firms.
Neurocrine to acquire Prader-Will drug in $2.9B Soleno buyout
BioPharma Dive
The deal hands Neurocrine a controversial medicine, Vykat, that achieved $190 million in sales last year but faces persistent questions about its growth trajectory and safety, according to Wall Street
Neurocrine Nabs Rare Obesity Disorder Drug in ‘Surprising’ $2.9B Soleno Deal
BioSpace
While an acquisition is a good exit for Soleno Therapeutics, the company’s acceptance of Neurocrine Biosciences’ $53-per-share offer came as a surprise to Stifel analysts given the potential growth of
Pharma Pipeline Stalls for First Time in Decades: Citeline
BioSpace
Some disease areas bucked the trend of shrinking pipelines, however, with immune and cardiovascular indications seeing an upward trend in investigational assets.